Skip to main content
. 2011 Jul 11;6:1487–1496. doi: 10.2147/IJN.S18535

Figure 5.

Figure 5

A) In vitro cumulative release and B) in vitro release rate of doxorubicin (DOX) from doxorubicin–dextran sulfate (DOX-DS) nanocomplexes (DOX: 60 μg/mL, DS/DOX [w/w]: 0.6) (n = 3). C) In vitro release of free DOX in phosphate buffer solution (pH 7.4), 37°C.